A multicenter, randomised, double-blind, non-comparative phase II trial of ZD1839 (Iressa) [gefitinib] and placebo in combination with chemotherapy with docetaxel as first-line treatment in patients with metastatic breast cancer

Trial Profile

A multicenter, randomised, double-blind, non-comparative phase II trial of ZD1839 (Iressa) [gefitinib] and placebo in combination with chemotherapy with docetaxel as first-line treatment in patients with metastatic breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2009

At a glance

  • Drugs Docetaxel; Gefitinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 May 2009 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 14 Dec 2007 Status changed from in progress to completed.
    • 12 Dec 2007 Results presented at SABCS 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top